Pharmaceutical

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the European Patent Office has issued a Notice of Intention to grant a patent related to certain methods of production for AV-101, the Company’s oral CNS drug candidate. As quoted in the press release: …

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the European Patent Office has issued a Notice of Intention to grant a patent related to certain methods of production for AV-101, the Company’s oral CNS drug candidate.

As quoted in the press release:

AV-101, an oral N-methyl-D-aspartate (NMDA) receptor glycine B (GlyB) antagonist, belongs to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators having the potential to treat MDD faster than current FDA-approved antidepressants commonly known as SSRIs and SNRIs, which target the neurotransmitters serotonin and/or norepinephrine, respectively.

“This patent will be the European counterpart to U.S. Patent No. 9,834,801 granted to us by the U.S. Patent and Trademark Office (USPTO) in December 2017,” stated Shawn Singh, Chief Executive Officer of VistaGen. “We are pleased that VistaGen will also have multiple patents relating to AV-101 in Europe. This is another important step in our strategy to secure long-term intellectual property protection for AV-101 in the world’s major pharmaceutical markets, thereby enhancing its commercial potential.”

Click here to read the full press release.

MARKETS

Markets
TSX19257.29+73.66
TSXV652.97+11.02
DOW30530.25+641.47
S&P 5003764.790.00
NASD11069.30+270.95
ASX6523.80+90.40

COMMODITIES

Commodities
Gold1838.24+6.91
Silver21.47-0.14
Copper3.91-0.14
Palladium1878.50+14.50
Platinum938.50+0.50
Oil103.80-5.72
Heating Oil4.18-0.06
Natural Gas6.75-0.06

DOWNLOAD FREE REPORTS

×